



ISTITUTO DI EMATOLOGIA
"L. E. A. SERAGNOLI"



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA,
ONCOLOGICA E SPERIMENTALE



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Policlinico S. Orsola-Malpighi

New Drugs in Hematology

President:

Pier Luigi Zinzani

Co-President: Michele Cavo

Honorary President: Sante Tura

Bologna,
Royal Hotel Carlton

May 9-11, 2016

BOLOGNA

BOLOGNA, ROYAL HOTEL CARLTON

Under the Auspices of

UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA



Faculty

Sergio	Amadori	Roma, Italy	Giovanni	Martinelli	Bologna, Italy
Michele	Baccarani	Bologna, Italy	Anthony	Mato	Philadelphia, USA
Giovanni	Barosi	Pavia, Italy	Ruben A.	Mesa	Phoenix, USA
Peter	Borchmann	Cologne, Germany	Philippe	Moreau	Nantes, France
Tim H.	Brummendorf	Aachen, Germany	Frank	Morschhauser	Lille, France
Fausto	Castagnetti	Bologna, Italy	Alison J.	Moskowitz	New York, USA
Michele	Cavo	Bologna, Italy	Owen A.	O'Connor	New York, USA
Francisco	Cervantes	Barcelona, Spain	Susan M.	O'Brien	Irvine, USA
Bruce D.	Cheson	Washington, USA	Michinori	Ogura	Gifu, Japan
Paolo	Corradini	Milano, Italy	Antonio	Palumbo	Torino, Italy
Steven E.	Coutré	Stanford, USA	Fabrizio	Pane	Napoli, Italy
Antonio	Cuneo	Ferrara, Italy	Francesco	Passamonti	Varese, Italy
Sven	de Vos	Los Angeles, USA	Ruth	Pettengell	London, United Kingdom
Tim	Demuth	Holzkirchen, Germany	Antonello	Pinto	Napoli, Italy
Hartmut	Dohner	Ulm, Germany	Pierluigi	Porcu	Columbus, USA
Martin	Dreyling	München, Germany	Vincent	Ribrag	Villejuif, France
Robin	Foà	Roma, Italy	Paul G.	Richardson	Boston, USA
Nathan H.	Fowler	Houston, USA	Gianantonio	Rosti	Bologna, Italy
Armando	Genazzani	Novara, Italy	Simon	Rule	Plymouth, United Kingdom
Marco	Gobbi	Genova, Italy	Giuseppe	Saglio	Torino, Italy
Hans C.	Hasselbalch	Roskilde, Denmark	Stephen	Schuster	Philadelphia, USA
Peter	Hillmen	Leeds, United Kingdom	Laurie H.	Sehn	Vancouver, Canada
Brian	Huntly	Cambridge, United Kingdom	Michele	Spina	Aviano - PN, Italy
Ilaria	Iacobucci	Memphis, USA	Anastasios	Stathis	Bellinzona, Switzerland
Carl H.	June	Philadelphia, USA	Eytan M.	Stein	New York, USA
Hagop	Kantarjian	Houston, USA	Richard M.	Stone	Boston, USA
Michael G.	Kauffman	Newton, USA	Aron	Thall	San Diego, USA
Arne	Kolstad	Oslo, Norway	Max S.	Topp	Würzburg, Germany
Shaji	Kumar	Rochester, USA	Alessandro M.	Vannucchi	Firenze, Italy
Steven	Le Gouill	Nantes, France	Thomas E.	Witzig	Rochester, USA
Sagar	Lonial	Atlanta, USA	Anas	Younes	New York, USA
Maurizio	Martelli	Roma, Italy	Pier Luigi	Zinzani	Bologna, Italy

Monday, May 9, 2016

9.00 a.m. *Welcome and Introduction*

Three recent “impressive” stories

Chairman: F. Pane

9.15 a.m. Brentuximab Vedotin in lymphomas - *A. Younes*

9.45 a.m. Blinatumumab in ALL - *M.S. Topp*

10.15 a.m. CAR T-cells - *C.H. June*

10.45 a.m. **Coffee Break**

Session I: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Passamonti, A.M. Vannucchi

11.00 a.m. Status of the art of treatment - *R.A. Mesa*

11.25 a.m. Ruxolitinib in myelofibrosis - *F. Passamonti*

11.40 a.m. Ruxolitinib in polycitemia vera - *A.M. Vannucchi*

11.55 a.m. New JAK2 inhibitors in MPNs and combination therapy - *F. Cervantes*

12.10 p.m. Interferons in MPNs - *H.C. Hasselbalch*

12.25 p.m. Newer drugs for myelofibrosis - *G. Barosi*

12.40 p.m. **Lunch**

Session II: Hodgkin's lymphoma

Chairmen: P. Borchmann, P.L. Zinzani

- 1.45 p.m.** Status of the art of treatment - *P. Borchmann*
- 2.10 p.m.** Nivolumab - *A. Younes*
- 2.25 p.m.** Pembrolizumab - *S. Schuster*
- 2.40 p.m.** Bendamustine - *A.J. Moskowitz*
- 2.55 p.m.** New Combo-steps - *A. Younes*

Session III: Chronic myeloid leukemia

Chairmen: M. Gobbi, G. Rosti

- 3.30 p.m.** Status of the art of treatment - *M. Baccarani*
- 3.55 p.m.** Nilotinib-based treatments and ABL001 - *F. Castagnetti*
- 4.15 p.m.** Dasatinib and combination - *G. Saglio*
- 4.30 p.m.** Bosutinib - *T.H. Brummendorf*
- 4.45 p.m.** Ponatinib - *G. Rosti*

Tuesday, May 10, 2016

Two “transversal on lymphomas” drugs

Chairman: P. Corradini

8.30 a.m. Bendamustine - *B.D. Cheson*

9.00 a.m. Lenalidomide - *T.E. Witzig*

Session IV: Non-Hodgkin’s lymphoma (I)

Chairmen: B.D. Cheson, A. Pinto

9.15 a.m. Status of the art of treatment - *B.D. Cheson*

9.40 a.m. Obinutuzumab - *L.H. Sehn*

9.55 a.m. Ublituximab - *N.H. Fowler*

10.10 a.m. MOR208 - *P.L. Zinzani*

10.25 a.m. anti-4-1BB - *A. Thall*

10.40 a.m. Polatuzumab - *F. Morschhauser*

10.55 a.m. Mogamulizumab - *M. Ogura*

11.15 a.m. 177Lu-HH1 (Betalutin) - *A. Kolstad*

11.30 a.m. CC-122 - *V. Ribrag*

11.45 a.m. EDO-S101 - *O.A. O’Connor*

12.00 p.m. IMG529 - *A. Stathis*

12.15 p.m. Selinexor - *M.G. Kauffman*

12.45 p.m. Pixantrone - *R. Pettengell*

1.00 p.m. **Lunch**

**New
Drugs
in
Hematology**

Session V: Non-Hodgkin's lymphoma (II)

Chairmen: N.H. Fowler, M. Martelli

- 2.00 p.m.** Venetoclax - *S. Rule*
- 2.15 p.m.** Idelalisib - *S. de Vos*
- 2.30 p.m.** Ibrutinib - *S. Rule*
- 2.45 p.m.** TGR-1202 - *O.A. O'Connor*
- 3.00 p.m.** Copanlisib - *M. Dreyling*
- 3.15 p.m.** Duvelisib - *N.H. Fowler*
- 3.30 p.m.** Acalabrutinib - *S. Le Gouill*
- 3.45 p.m.** Tazemetostat - *V. Ribrag*

Session VI: Chronic Lymphocytic Leukemia

Chairmen: A. Cuneo, R. Foà

- 4.15 p.m.** Status of the art of management - *S.M. O'Brien*
- 4.45 p.m.** Ibrutinib - *P. Hillmen*
- 5.00 p.m.** Idelalisib - *S.E. Coutré*
- 5.15 p.m.** Venetoclax - *P. Hillmen*
- 5.30 p.m.** Acalabrutinib - *S.M. O'Brien*
- 5.45 p.m.** Duvelisib - *P. Porcu*
- 6.00 p.m.** TGR-1202 and Ublituximab - *A. Mato*

Wednesday, May 11, 2016

Session VII: Multiple myeloma

Chairmen: M. Cavo, S. Lonial

- 8.30 a.m.** Status of the art of treatment - *A. Palumbo*
- 8.55 a.m.** Modelling of disease evolution: what have we learned and how can we drive future treatment strategies? - *P.G. Richardson*
- 9.10 a.m.** Immune checkpoint inhibitors and immune-based therapies - *P.G. Richardson*
- 9.25 a.m.** New insights into optimal use of PIs and IMiDs based on sensitizing targets and biomarkers - *P. Moreau*
- 9.40 a.m.** Histone deacetylase and kinase inhibitors - *S. Lonial*
- 9.55 a.m.** Monoclonal antibodies and their integration into the modern therapeutic algorithms - *M. Cavo*
- 10.10 a.m.** Is personalized therapy ready for primetime? - *S.K. Kumar*

Other two “interesting issues”

Chairmen: A. Genazzani, P.L. Zinzani

- 10.30 a.m.** Rituximab biosimilars - *T. Demuth, A. Genazzani*
- 11.00 a.m.** The role of liposomal doxorubicin in DLBCL lymphomas - *M. Spina*

Session VIII: Acute leukemia

Chairmen: S. Amadori, G. Martinelli

- 11.30 a.m.** Status of the art of treatment - *H. Dohner*
- 11.55 a.m.** Targeting BET in acute myeloid leukemia - *B. Huntly*

- 12.10 p.m.** IDH2 inhibitors in acute myeloid leukemia - *E.M. Stein*
- 12.25 p.m.** FLT3 inhibitors in acute myeloid leukemia - *R.M. Stone*
- 12.40 p.m.** Inotuzumab ozogamicin in acute lymphoblastic leukemia - *H. Kantarjian*
- 12.55 p.m.** BCR-ABL like in acute lymphoblastic leukemia - *I. Iacobucci*
- 13.10 p.m.** The role of RO5503781 in acute myeloid leukemia - *G. Martinelli*
-
- 1.30 p.m.** *Conclusions and Arrivederci*
-
- 1.45 p.m.** **Lunch**



GENERAL INFORMATION

MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361 - Fax +39 051 249724

OFFICIAL LANGUAGE

English

REGISTRATION FEE

Euro 400,00 (Italian VAT included)

The registration fee includes: Conference kit, participation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.

BADGE

All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

A request for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: **ID 828-155057**.
- No. **10 CME** credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), biologists and chemists.
- Educational objective: "guidelines-protocols-procedures".

EBAH CME CREDITS

The program of the "New Drugs in Hematology" meeting has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH has approved this educational activity for no. **20 CME** credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org> even on site.

CHANGES

Parts of the program may be changed without notice.

ACKNOWLEDGEMENTS

abbvie

 Bristol-Myers Squibb

 Celgene

 GILEAD

janssen  PHARMACEUTICAL COMPANIES
of Johnson & Johnson

 Roche

AMGEN®

 BAYER

 Infinity™
PHARMACEUTICALS

 Pfizer Oncology

 SANDOZ
a Novartis company

 TG Therapeutics

 Acerta Pharma

IMMUNOGEN

 Karyopharm™
Therapeutics

 MSD

morphosys

 mundi pharma

 Takeda

 TEVA

 ARIAD™

 astellas
ONCOLOGY
Changing Tomorrow to Cancer Care

 Boehringer
Ingelheim

 Epizyme

KYOWA KIRIN

 NORDIC
NANOVECTOR

 SERVIER

New in Drugs Hematology

Scientific Secretariat

Pier Luigi Zinzani

Istituto di Ematologia

“Lorenzo e Ariosto Seràgnoli”

Via Massarenti, 9 - 40138 Bologna, Italy

Phone +39 051 6363680 - Fax +39 051 6364037

e-mail: pierluigi.zinzani@unibo.it

Organizing Secretariat

Studio E.R. Congressi

Via Marconi, 36 - 40122 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

e-mail: ercongressi@ercongressi.it

www.ercongressi.it